Special Issue

Advances in Personalized Treatment of Cancer (Powered By: 4oncommunity)

Message from the Guest Editors

We are experiencing an amazing era of advances in the diagnosis and treatment of cancer. In this evolving scenario, predictive molecular pathology is called to face new challenges. Our increased diagnostic resolution, coupled with the integration of clinicopathologic information, and big molecular data, is allowing for a growth in the selective capacity of molecular targeted treatments. Novel biomarkers at genomic, transcriptomic, proteomic, and immunologic levels have been discovered, and more accurate testing methods and guidelines are expected. These biomarkers are strongly impacting treatment decision making in patients with cancer. This Special Issue is edited by the Scientific Board of 4oncommunity (www.4oncommunity.com Twitter: @4oncommunity) to provide a comprehensive portrait of the current state of knowledge of biomarkers for the clinical management of cancer patients. One of the aims of this initiative is to foster a novel approach in collaborating between scientists working on cancer. We especially welcome review articles (either systematic or discursive), original translational research studies, and short communications.

Guest Editors

Prof. Dr. Matteo Fassan

Dr. Umberto Malapelle

Dr. Nicola Fusco

Prof. Dr. Fabio Pagni

Dr. Carmen Criscitiello

Dr. Sara Pilotto

Deadline for manuscript submissions

closed (20 July 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/97984

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

